AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00333294
- Locations
- 🇫🇷
Research Site, Nantes, France
🇫🇷Research SIte, Paris, France
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
- Conditions
- Hypercholesteremia
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT00329160
- Locations
- 🇯🇵
Research Site, Yokohama, Japan
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
- Conditions
- SchizophreniaSchizoaffective Disorders
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00328978
- Locations
- 🇨🇦
Research Site, Saskatoon, Saskatchewan, Canada
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 876
- Registration Number
- NCT00329264
- Locations
- 🇺🇸
Research SIte, Fall River, Massachusetts, United States
🇺🇸Research Site, Charleston, West Virginia, United States
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
- Conditions
- Hypercholesterolaemia
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00329173
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT00329446
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
Faslodex Advanced Breast Cancer Local Chinese Study
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00327769
- Locations
- 🇨🇳
Research Site, Xi AN, China
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00328120
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1306
- Registration Number
- NCT00327015
- Locations
- 🇺🇸
Newark Physician Associates, Newark, Ohio, United States
🇺🇸East Bay Clinical Trial Center, Concord, California, United States
🇺🇸Community Clinical Trials, Orange, California, United States
Prevention of Asthma Relapse After Discharge From Emergency
- Conditions
- Asthma
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00326053
- Locations
- 🇨🇦
Research Site, Quebec, Canada